drugset / Trial / NCT05184491
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
Phase 4
Unknown
500 enrolled
National Liver Institute, Egypt
Future pharmaceutical industries · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients who failed previous therapies.
Timeline
- Start
- 2021-10-15
- Primary completion
- 2022-02-01
- Completion
- 2022-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | 1 g | — |
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Doxycycline | Small molecule | 100 mg | — |
| Subject | Levofloxacin | Small molecule | 750 mg | — |
| Subject | Moxifloxacin | Small molecule | 400 mg | — |
| Subject | Nitazoxanide | Other / unclassified | 500 mg | — |
| Background | Lansoprazole | Other / unclassified | 40 mg | — |